
Releases
New Proteomics Blood Test Hits 92% Accuracy for Early Breast Cancer
A peer-reviewed study published in Breast Cancer: Targets and Therapy confirms that a new liquid biopsy test, Certitude, identifies early-stage breast cancer with 92.6% sensitivity. By analyzing protein signals rather than DNA, the test overcomes long-standing limitations in detecting tumors that shed minimal genetic material into the bloodstream.



























